Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.25
- Piotroski Score 1.00
- Grade Buy
- Symbol (RLMD)
- Company Relmada Therapeutics, Inc.
- Price $3.23
- Changes Percentage (-4.15%)
- Change -$0.14
- Day Low $3.10
- Day High $3.53
- Year High $7.22
Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/05/2024
- Fiscal Year End N/A
- Average Stock Price Target $7.00
- High Stock Price Target $8.00
- Low Stock Price Target $2.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$3.13
- Trailing P/E Ratio -0.94
- Forward P/E Ratio -0.94
- P/E Growth -0.94
- Net Income $-98,791,746
Income Statement
Quarterly
Annual
Latest News of RLMD
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Institutional investors have a lot riding on Relmada Therapeutics, Inc. (NASDAQ:RLMD) with 48% ownership
Research on ownership and analyst forecasts data are crucial in understanding stock opportunities. Institutions hold a significant stake in Relmada Therapeutics, influencing its performance. Analysts ...
By Yahoo! Finance | 2 months ago